v3.26.1
Acquisitions
 6 Months Ended
Jun. 30, 2026
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
Acquisitions
Note 4 — Acquisitions
During the three and six months ended June 30, 2026 and 2025, the Company did not consummate any acquisitions that were material, individually or in the aggregate.
Contingent consideration
Contingent consideration recorded relates to the Company's business combinations and asset acquisitions. As discussed in Note 3 — Significant accounting policies, contingent consideration payable is subject to significant judgment and estimates, such as projected future revenue. See Note 27 — Fair value measurements for further discussion surrounding the inputs utilized in the fair value of contingent consideration.
The changes in the Company's contingent consideration liability as of June 30, 2026 and December 31, 2025 were as follows:
EMMAC(1)
NGC(2)
Total
Total contingent consideration liability, December 31, 2024$2,837 $3,310 $6,147 
Cash payments of contingent consideration— (3,236)(3,236)
Issuance of SVS as settlement of contingent consideration— (497)(497)
Revaluation of contingent consideration306 335 641 
Effect of exchange rate differences215 — 215 
Gain (loss) on contingent consideration not paid— 88 88 
Total contingent consideration liability, December 31, 20253,358 — 3,358 
Revaluation of contingent consideration572 — 572 
Effect of exchange rate differences(51)— (51)
Total contingent consideration liability, June 30, 2026
3,879 — 3,879 
'Contingent consideration liability - net of current$3,879 $— $3,879 
(1) Contingent on the ability of Curaleaf International Holdings Limited ("Curaleaf International") to obtain a recreational cannabis license in Europe, payable in both cash and SVS upon achievement.
(2) Contingent obligation was tied to Northern Green Canada ("NGC") achieving certain margin targets during the fiscal year ending December 31, 2024.
Deferred consideration
The changes in the Company's deferred consideration liability as of June 30, 2026 and December 31, 2025 were as follows:
Tryke(1)
NRPC(2)
Curaleaf Poland(3)
Four20 Pharma (5)
Other(4)
Total
Total deferred consideration liability, December 31, 2024$32,564 $2,000 $504 $— $— $35,068 
Deferred consideration recognized on acquisition— — — — 920 920 
Accretion of interest on deferred consideration2,436 — — — — 2,436 
Effect of exchange rate differences— — 17 — 46 63 
Change in fair value on deferred consideration paid— — (46)— — (46)
Issuance of SVS as settlements of deferred consideration— — (77)— — (77)
Cash payments of deferred consideration(35,000)— (398)— — (35,398)
Total deferred consideration liability, December 31, 2025— 2,000 — — 966 2,966 
Deferred consideration recognized on acquisition— — — 14,197 — 14,197 
Accretion of interest on deferred consideration— — — 139 184 323 
Effect of exchange rate differences— — — (309)(17)(326)
Post-closing purchase price adjustment— (182)— — — (182)
Cash payments of deferred consideration— (618)— — — (618)
Total deferred consideration liability, June 30, 2026— 1,200 — 14,027 1,133 16,360 
Less: Deferred consideration liability - current— (1,075)— (14,027)(1,133)(16,235)
Deferred consideration liability as of June 30, 2026$— $125 $— $— $— $125 
(1) Related to the second and third anniversary payment due from the Company to the sellers of Tryke that was settled-in-full by October 2025.
(2) Represents amounts withheld in connection with the acquisition of Natural Remedy Patient Center LLC ("NRPC") as security for indemnification obligations. In January 2026, upon receipt of a final, non-appealable order, the $2.0 million holdback became payable. The Company retained $1.2 million for potential tax exposure (scheduled for release in August 2026 and August 2027, subject to IRS claims) and deducted legal fees incurred during the litigation as permitted under the purchase agreement. The remaining amount, net of the tax holdback and legal fees, was paid in February 2026.
(3) Related to Curaleaf Poland’s achievement of certain earnings metrics during the fiscal year ending December 31, 2024. On April 14, 2025, the Company settled this obligation through a cash payment of $0.4 million and the issuance of 32,017 SVS.
(4) Incurred in connection with an individually immaterial acquisition consummated during the second quarter of 2025 within the Company’s international operations.
(5) Represents cash consideration of $14.2 million withheld in connection with the acquisition of the remainder of Four20 Pharma GmbH ("Four20 Pharma). Refer to Note 18 — Temporary equity and redeemable non-controlling interests for further details.